John Flavin, Portal Innovations CEO, joins 'Fast Money' to talk what we can expect to see from the J.P. Morgan Healthcare ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

LAS VEGAS, NV / ACCESSWIRE / / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...

NDAQ:IRMD) IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues ...

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

43rd Annual J.P. Morgan Healthcare Conference – Company Presentation Date: Wednesday, January 15, 2025 Time: 3:45 p.m. - 4:25 p.m. PT Location: The Westin St. Francis Hotel, San Francisco, CA ...

Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...

Here is a list of healthcare conferences and links to registration.  Special thanks to Peter Grant and Global Healthcare LLC ...